Assessing the efficacy and safety in novel drug candidates for Alzheimer's disease employs a rigorous evaluation framework. Preclinical studies usually involve in vitro and in vivo models to assess the potential efficacy in targeting disease-related pathways. Once promising candidates emerge, they progress through clinical trials that are conducte